Table 3 Analysis results

HFSR incidence ratio

 All grades

66.7% (95% CI: 46.0–83.5%)

76%⁶, 58.2%⁷

 Grade 1

22.2% (95% CI: 9.6–42.3%)

 Grade 2

37.0% (95% CI: 19.4–57.6%)

 Grade 3

7.4%^* (80% CI: 2.0–18.5%)

21%^6, 19%⁷

Incidence of regorafenib dosage change (discontinuation/interruption/dosage reduction) due to HFSR

 Discontinuation

0%

 Interruption

11% (95% CI: 2.4–29.2%)

 Dosage reduction

0%

Incidence of regorafenib dosage changes due to adverse effects related to aluminum chloride

0%

Time to development of HFSR of any grade, median days

15.0 days (95% CI: 8.0–47.0)

7.0 days [17]

Time to improvement from HFRS ≥ grade 2 to ≤ grade 1, median days

8.0 days (95% CI: 4.0–10.0)